Literature DB >> 10202144

Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2.

T Unger1, T Juven-Gershon, E Moallem, M Berger, R Vogt Sionov, G Lozano, M Oren, Y Haupt.   

Abstract

In response to environmental stress, the p53 phosphoprotein is stabilized and activated to inhibit cell growth. p53 stability and activity are negatively regulated by the murine double minute (Mdm2) oncoprotein in an autoregulatory feedback loop. The inhibitory effect of Mdm2 on p53 has to be tightly regulated for proper p53 activity. Phosphorylation is an important level of p53 regulation. In response to DNA damage, p53 is phosphorylated at several N-terminal serines. In this study we examined the role of Ser20, a potential phosphorylation site in human p53, in the regulation of p53 stability and function. Substitution of Ser20 by Ala (p53-Ala20) significantly increases the susceptibility of human p53 to negative regulation by Mdm2 in vivo, as measured by apoptosis and transcription activation assays. Mutation of Ser20 to Ala renders p53 less stable and more prone to Mdm2-mediated degradation. While the in vitro binding of p53 to Mdm2 is not increased by the Ala20 mutation, the same mutation results in a markedly enhanced binding in vivo. This is consistent with the conclusion that phosphorylation of Ser20 in vivo attenuates the binding of wild-type p53 to Mdm2. Peptides bearing non-phosphorylated Ser20 or Ala20 compete with p53 for Mdm2 binding, while a similar peptide with phosphorylated Ser20 does not. This implies a critical role for Ser20 in modulating the negative regulation of p53 by Mdm2, probably through phosphorylation-dependent inhibition of p53-Mdm2 interaction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10202144      PMCID: PMC1171266          DOI: 10.1093/emboj/18.7.1805

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  75 in total

1.  Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest.

Authors:  L C Huang; K C Clarkin; G M Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

Review 2.  p53 in growth control and neoplasia.

Authors:  T M Gottlieb; M Oren
Journal:  Biochim Biophys Acta       Date:  1996-06-07

Review 3.  p53 Phosphorylation: biochemical and functional consequences.

Authors:  G J Milczarek; J Martinez; G T Bowden
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

Review 4.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

5.  Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.

Authors:  P H Kussie; S Gorina; V Marechal; B Elenbaas; J Moreau; A J Levine; N P Pavletich
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

6.  mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts.

Authors:  K M McMasters; R Montes de Oca Luna; J R Peña; G Lozano
Journal:  Oncogene       Date:  1996-10-17       Impact factor: 9.867

7.  Mutation of phosphoserine 389 affects p53 function in vivo.

Authors:  M Hao; A M Lowy; M Kapoor; A Deffie; G Liu; G Lozano
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

Review 8.  How phosphorylation regulates the activity of p53.

Authors:  W T Steegenga; A J van der Eb; A G Jochemsen
Journal:  J Mol Biol       Date:  1996-10-25       Impact factor: 5.469

Review 9.  Biological and clinical importance of the p53 tumor suppressor gene.

Authors:  V E Velculescu; W S El-Deiry
Journal:  Clin Chem       Date:  1996-06       Impact factor: 8.327

10.  Cell type-specific inhibition of p53-mediated apoptosis by mdm2.

Authors:  Y Haupt; Y Barak; M Oren
Journal:  EMBO J       Date:  1996-04-01       Impact factor: 11.598

View more
  88 in total

1.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.

Authors:  N H Chehab; A Malikzay; E S Stavridi; T D Halazonetis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  p53 down-regulates CHK1 through p21 and the retinoblastoma protein.

Authors:  V Gottifredi; O Karni-Schmidt; S S Shieh; C Prives
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

3.  p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2.

Authors:  A Ito; C H Lai; X Zhao; S Saito; M H Hamilton; E Appella; T P Yao
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

Review 4.  Molecular interaction map of the mammalian cell cycle control and DNA repair systems.

Authors:  K W Kohn
Journal:  Mol Biol Cell       Date:  1999-08       Impact factor: 4.138

5.  Stress signals utilize multiple pathways to stabilize p53.

Authors:  M Ashcroft; Y Taya; K H Vousden
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

6.  MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins.

Authors:  E Kobet; X Zeng; Y Zhu; D Keller; H Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

Review 7.  Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.

Authors:  M Ljungman
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

8.  WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase.

Authors:  Fei Su; Michael Overholtzer; Daniel Besser; Arnold J Levine
Journal:  Genes Dev       Date:  2002-01-01       Impact factor: 11.361

Review 9.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

10.  Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation.

Authors:  Mark A McCoy; Jennifer J Gesell; Mary M Senior; Daniel F Wyss
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.